Serveur d'exploration sur les relations entre la France et l'Australie

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Dose faible And NotKerry Taylor

List of bibliographic references

Number of relevant bibliographic references: 16.
Ident.Authors (with country if any)Title
000622 Hagop M. Kantarjian [États-Unis] ; Giovanni Martinelli [Italie] ; Elias J. Jabbour [États-Unis] ; Alfonso Ouintas-Cardama [États-Unis] ; Kiyoshi Ando [Japon] ; Jacques-Olivier Bay [France] ; Andrew Wei [Australie] ; Stefanie Gröpper [Allemagne] ; Cristina Papayannidis [Italie] ; Kate Owen [Royaume-Uni] ; Laura Pike [Royaume-Uni] ; Nicola Schmitt [Royaume-Uni] ; Paul K. Stockman [Royaume-Uni] ; Aristoteles Giagounidis [Allemagne]Stage I of a Phase 2 Study Assessing the Efficacy, Safety, and Tolerability of Barasertib (AZD1152) Versus Low-Dose Cytosine Arabinoside in Elderly Patients With Acute Myeloid Leukemia
000F32 Hagop M. Kantarjian [États-Unis] ; Xavier G. Thomas [France] ; Anna Dmoszynska [Pologne] ; Agnieszka Wierzbowska [Pologne] ; Grzegorz Mazur [Pologne] ; Jiri Mayer [République tchèque] ; Jyh-Pyng Gau [Taïwan] ; Wen-Chien Chou [Taïwan] ; Rena Buckstein [Canada] ; Jaroslav Cermak [République tchèque] ; Ching-Yuan Kuo [Taïwan] ; Albert Oriol [Espagne] ; Farhad Ravandi [États-Unis] ; Stefan Faderl [États-Unis] ; Jacques Delaunay [France, Australie] ; Daniel Lysak [République tchèque] ; Mark Minden ; Christopher ArthurMulticenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
002116 Pierre Fenaux [France] ; Norbert Gattermann [Allemagne] ; John F. Seymour [Australie] ; Eva Hellström-Lindberg [Suède] ; Ghulam J. Mufti [Royaume-Uni] ; Ulrich Duehrsen [Allemagne] ; Steven D. Gore [États-Unis] ; Fernando Ramos [Espagne] ; Odile Beyne-Rauzy [France] ; Alan List [États-Unis] ; David Mckenzie [États-Unis] ; Jay Backstrom [États-Unis] ; Charles L. Beach [États-Unis]Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C
002238 M.-A. Maire [France] ; E. Bazin [France] ; V. Fessard [France] ; C. Rast [France] ; A. R. Humpage [Australie] ; P. Vasseur [France]Morphological cell transformation of Syrian hamster embryo (SHE) cells by the cyanotoxin, cylindrospermopsin
003153 Paul A. Fowler [Royaume-Uni] ; Natalie J. Dora [Royaume-Uni] ; Helen Mcferran [Royaume-Uni] ; Maria R. Amezaga [Royaume-Uni] ; David W. Miller [Australie] ; Richard G. Lea [Royaume-Uni] ; Phillip Cash [Royaume-Uni] ; Alan S. Mcneilly [Royaume-Uni] ; Neil P. Evans [Royaume-Uni] ; Corinne Cotinot [France] ; Richard M. Sharpe [Royaume-Uni] ; Stewart M. Rhind [Royaume-Uni]In utero exposure to low doses of environmental pollutants disrupts fetal ovarian development in sheep
003228 B. Melichar [République tchèque] ; P. Koralewski [Pologne] ; A. Ravaud [France] ; A. Pluzanska [Pologne] ; S. Bracarda [Italie] ; C. Szczylik [Pologne] ; C. Chevreau [France] ; M. Filipek [Pologne] ; R. Delva [France] ; E. Sevin [France] ; S. Negrier [France] ; J. Mckendrick [Australie] ; A. Santoro [Italie] ; P. Pisa [Suisse] ; B. Escudier [France]First-line bevacizumab combined with reduced dose interferon-a2a is active in patients with metastatic renal cell carcinoma
003F06 M. Salvadori [Italie] ; A. Rosati [Italie] ; E. Bertoni [Italie] ; A. Bock [Suisse] ; J. Chapman [Australie] ; B. Dussol [France] ; L. Fritsche [Allemagne] ; V. Kliem [Allemagne] ; Y. Lebranchu [France] ; F. Oppenheimer [Espagne] ; E. Pohanka [Autriche] ; G. Tufveson [Suède] ; M. Soergel [Suisse]Low 1-year cyclosporine microemulsion doses are associated with better 5-year renal graft function : An insight from MOST, a multinational observational study
004579 B. K. Kr Mer [Allemagne] ; H.-H. Neumayer [Allemagne] ; R. Stahl [Allemagne] ; M. Pietrzyk [Allemagne] ; B. Krüger [Allemagne] ; B. Pfalzer [Allemagne] ; B. Bourbigot [France] ; S. Campbell [Australie] ; J. Whelchel [États-Unis] ; J. Eris [Australie] ; S. Vitko [République tchèque] ; K. Budde [Allemagne]Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab
004947 Nicola De Luca [Italie] ; Roland G. Asmar [France] ; Gérard M. London [France] ; Michael F. O'Rourke [Australie] ; Michel E. Safare [France]Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects
004A68 Gérard M. London [France] ; Roland G. Asmar [France] ; Michaël F. O'Rourke [Australie] ; Michel E. Safar [France]Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: Comparison with atenolol
005833 Roland G. Asmar [France] ; Gérard M. London [France] ; Michael E. O'Rourke [Australie] ; Michel E. Safar [France]Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: A comparison with atenolol
005C26 J. Chalmers [Australie] ; A. Castaigne [France] ; T. Morgan [Australie] ; C. Chastang [France]Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients
006065 A. Castaigne [France] ; J. Chalmers [Australie] ; T. Morgan [Australie] ; C. Chastang [France] ; L. Feldmann [France] ; D. Guez [France]Efficacy and safety of an oral fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination : A randomized, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension
006241 G. Pearce [Australie] ; P. F. J. Ryan [Australie] ; P. D. Delmas [France] ; D. A. Tabensky [Australie] ; E. Seeman [Australie]The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica
006667 J. C. Speller [Royaume-Uni] ; T. R. E. Barnes [Royaume-Uni] ; D. A. Curson [Royaume-Uni] ; C. Pantelis [Australie] ; J. L. Alberts [France]One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms : Amisulpride v. haloperidol
006749 J.-L. Cracowski [France] ; O. Chavanon ; M. Durand ; E. Borrel ; P. Devillier ; J.-M. Mallion ; D. Blin ; B. BuxtonEffect of low-dose positive inotropic drugs on human internal mammary artery flow. Commentary

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024